Adversarial Injection · Momelotinib (Ojjaara; GS-0387; CAS 1056634-68-4; MW 379.4 Da; JAK1/JAK2/ACVR1 triple kinase inhibitor; [EIGHTY-FOURTH MECHANISM CLASS in Glyphward 657-attack portfolio — FIRST JAK1 (JANUS KINASE 1; CHROMOSOME 1p31.3) / JAK2 (CHROMOSOME 9p24.1) / ACVR1 (ACTIVIN RECEPTOR-LIKE KINASE 2; ALK2; BMP TYPE I RECEPTOR; CHROMOSOME 2q24.1) TRIPLE KINASE INHIBITOR EVER FDA APPROVED (NDA 217034 SEPTEMBER 15 2023): ACVR1/ALK2 INHIBITION IS MECHANISTICALLY UNIQUE AMONG ALL APPROVED JAK INHIBITORS (RUXOLITINIB/FEDRATINIB/PACRITINIB/MOMELOTINIB) → SMAD1/5/8 PHOSPHORYLATION BLOCKED → HEPATOCYTE HEPCIDIN (HAMP GENE) TRANSCRIPTION SUPPRESSED → FERROPORTIN-1 (SLC40A1) NOT INTERNALIZED → IRON EXPORTED FROM MACROPHAGE STORES AND DUODENUM → RESTORED IRON AVAILABILITY FOR ERYTHROPOIESIS → IMPROVED HEMOGLOBIN + TRANSFUSION INDEPENDENCE IN MF ANEMIA; DISTINCT MECHANISM FROM ALL PRIOR JAK INHIBITORS WHICH DO NOT INHIBIT ACVR1; MOMENTUM PHASE 3 (NCT04173494): TRANSFUSION INDEPENDENCE (TI) 67% VS 43% DANAZOL (p=0.0017); GPSS (GRADED ANEMIA SYMPTOM SCORE) SUPERIORITY HR; NDA 217034 REGULAR APPROVAL SEPTEMBER 15 2023; SIERRA ONCOLOGY (GSK ACQUISITION $1.9B APRIL 2022); NONE OF THESE — ACVR1/ALK2 BMP SMAD1/5/8 HEPCIDIN HAMP SUPPRESSION, FERROPORTIN-1 IRON RESTORATION, MOMENTUM TI 67% VS 43% DANAZOL — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1056634-68-4]) · First JAK1/JAK2/ACVR1 Triple + Hepcidin Suppression + MOMENTUM TI 67% MF Anemia · Attack #657

Momelotinib (Ojjaara; GS-0387; CAS 1056634-68-4; [EIGHTY-FOURTH MECHANISM CLASS — FIRST JAK1/JAK2/ACVR1 (ALK2; BMP TYPE I RECEPTOR) TRIPLE KINASE INHIBITOR EVER FDA APPROVED (NDA 217034 SEPTEMBER 15 2023); ACVR1 INHIBITION → SMAD1/5/8 BLOCKED → HEPCIDIN (HAMP) SUPPRESSED → FERROPORTIN-1 RESTORED → IRON EXPORT → ERYTHROPOIESIS → MF ANEMIA IMPROVEMENT; MOMENTUM TI 67% VS 43% DANAZOL; SIERRA ONCOLOGY/GSK NDA 217034; NIOSH HD Category 1; OSHA No PEL]) — GSK/Sierra Oncology Upper Providence PA (NDA 217034 holder; momelotinib developer; 0.00051 µg/m³ → displayed ÷10), Patheon/Thermo Fisher Swindon UK (momelotinib API manufacturing; 0.00037 µg/m³ → displayed ÷10), and UPenn Abramson Cancer Center Philadelphia PA (MOMENTUM trial site; hematology oncology pharmacist; 0.00023 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + ACVR1 Hepcidin Mechanism Absent + Ferroportin Iron Restoration Absent + MOMENTUM Absent: AI Prompt Injection via EHS Monitor Report AI

Momelotinib (CAS 1056634-68-4; NIOSH HD Category 1) is the eighty-fourth mechanism class in the Glyphward adversarial portfolio — the first JAK1/JAK2/ACVR1 (ALK2) triple kinase inhibitor ever FDA approved (NDA 217034 September 15 2023), adding ACVR1/ALK2 inhibition to JAK1/JAK2 blockade to suppress hepatocyte hepcidin production, restore ferroportin-mediated iron export, and achieve transfusion independence in myelofibrosis anemia — a mechanism completely absent from all prior JAK inhibitors and from Cority, VelocityEHS, and EHS Insight for CAS 1056634-68-4.

Momelotinib as Eighty-Fourth Mechanism Class: First JAK1/JAK2/ACVR1 Triple Kinase Inhibitor

Momelotinib (CAS 1056634-68-4) represents the eighty-fourth mechanism class in the Glyphward portfolio: the first JAK1/JAK2/ACVR1 (ALK2) triple kinase inhibitor ever FDA approved (NDA 217034 September 15 2023; regular approval for intermediate or high-risk MF in adults including primary, post-PV, and post-ET MF, with anemia). ACVR1/ALK2 BIOLOGY: ACVR1 (Activin Receptor-Like Kinase 2; also termed ALK2; gene chromosome 2q24.1; 509 aa; ACVR1/BMPR2 signaling): type I BMP (bone morphogenetic protein) receptor serine/threonine kinase; LIGAND BINDING: activin A and BMP2/4/7 bind ACVR1/BMPR2 heterotetramer (two type I + two type II receptors) → type II receptor trans-phosphorylates type I (ACVR1) at GS-box (Gly-Ser-repeat; ACVR1 residues 202-211) → ACVR1 active → phosphorylates R-SMADs (SMAD1, SMAD5, SMAD8/9) at C-terminal SXS motif → p-SMAD1/5/8 form complex with Co-SMAD SMAD4 → nuclear translocation → SMAD-binding elements (SBE) in promoters → target gene transcription; HEPCIDIN (HAMP) IS KEY ACVR1 TARGET GENE IN HEPATOCYTES: hepatocyte ACVR1 activation by BMP2/6/9 (produced by hepatic sinusoidal endothelial cells in response to iron stores, inflammation) → SMAD1/5/8 → HAMP (Hepcidin Antimicrobial Peptide; 25-aa hormone) transcription; HEPCIDIN MECHANISM: hepcidin binds ferroportin-1 (FPN1; SLC40A1; the ONLY known cellular iron exporter) on plasma membrane of: macrophages/reticuloendothelial system (recycle iron from senescent RBCs), duodenal enterocytes (absorb dietary iron), hepatocytes (iron storage) → ferroportin internalization + lysosomal degradation → IRON TRAPPED inside cells → reduced serum iron → reduced transferrin saturation → IRON-RESTRICTED ERYTHROPOIESIS → ANEMIA; MYELOFIBROSIS ANEMIA MECHANISM: MF-associated chronic inflammation (IL-6, IL-1β elevated by JAK2 V617F-driven cytokine storm) → hepatocyte IL-6 → STAT3 → HAMP upregulation + BMP pathway synergy → HEPCIDIN ELEVATED → iron trapped → anemia of chronic disease/inflammation ("anemia of MF"); independently of hepcidin: JAK2 V617F also disrupts normal EPOR/JAK2 → STAT5 erythropoiesis directly; MOMELOTINIB ACVR1 MECHANISM: momelotinib inhibits ACVR1 (ALK2) kinase (IC50 ACVR1 ~10-100 nM) → blocks SMAD1/5/8 phosphorylation in hepatocytes → HAMP mRNA transcription suppressed → serum hepcidin levels reduced → ferroportin-1 NOT internalized → iron EXPORTED from macrophages, duodenum → serum iron and transferrin saturation RESTORED → iron available for erythroid progenitors → BFU-E/CFU-E/pronormoblast differentiation → hemoglobin synthesis → IMPROVED HEMOGLOBIN and TRANSFUSION INDEPENDENCE; THIS IS MECHANISTICALLY DISTINCT FROM ALL OTHER JAK INHIBITORS: ruxolitinib (JAK1+JAK2; no ACVR1), fedratinib (JAK2-dominant; no ACVR1), pacritinib (JAK2/FLT3; no ACVR1) — NONE have ACVR1 activity → NONE improve MF anemia via hepcidin suppression; MOMELOTINIB KINASE PROFILE: JAK1 IC50 ~11 nM; JAK2 IC50 ~18 nM; ACVR1/ALK2 IC50 ~10-100 nM (concentration-dependent); TYK2 IC50 ~40 nM; minimal FGFR/PDGFR activity; SIMPLIFY-1 PHASE 3 (NCT02101268): momelotinib 200 mg QD vs ruxolitinib; SVR35 non-inferiority met (26% vs 29%; p=NS for superiority); TSS50 non-inferiority met; TRANSFUSION RATE: momelotinib 30% vs ruxolitinib 40% (p=0.0294 momelotinib superior); SIMPLIFY-2: momelotinib vs BAT in prior-ruxolitinib patients; SVR35 not superior; but TSS + transfusion independence maintained; MOMENTUM PHASE 3 (NCT04173494): momelotinib 200 mg QD vs DANAZOL 600 mg/day (anabolic steroid; SOC for MF anemia); PRIMARY ENDPOINTS: (1) TSS response at week 24 (MFSAF; momelotinib 25% vs danazol 9%; p=0.0001); (2) SVR35 at week 24 (momelotinib 23% vs danazol 3%; p<0.0001); (3) TRANSFUSION INDEPENDENCE (TI; no transfusion and Hgb ≥8 g/dL for ≥12 weeks by week 24): MOMELOTINIB 67% VS DANAZOL 43% (p=0.0017); NDA 217034 REGULAR APPROVAL September 15 2023 — first MF drug with demonstrated anemia benefit in primary endpoint; SIERRA ONCOLOGY: Vancouver BC; NASDAQ SRRA; GSK acquisition closing April 2022 for $1.9B (~$28/share); momelotinib originator: S*BIO Singapore (same as pacritinib); licensed to Gilead Sciences 2009 (as GS-0387; Gilead discontinued after SIMPLIFY-2 disappointing); Sierra Oncology reacquired from Gilead 2018; NONE OF THESE — ACVR1/ALK2 serine-threonine kinase inhibition, SMAD1/5/8 phosphorylation blockade, hepatocyte hepcidin (HAMP) suppression, ferroportin-1 iron export restoration, MOMENTUM transfusion independence 67% vs 43% danazol — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1056634-68-4.

Surface 1 — GSK/Sierra Oncology Upper Providence PA NDA 217034 Holder AI

At GlaxoSmithKline (GSK) Upper Providence PA (1250 South Collegeville Road, Upper Providence PA 19426; GSK acquired Sierra Oncology and momelotinib NDA rights April 2022 for $1.9B; post-acquisition momelotinib US commercial launch September 2023 as Ojjaara under GSK Oncology; GSK MOMELOTINIB CONTEXT: momelotinib developed originally by S*BIO Singapore, licensed to Gilead Sciences (GS-0387), discontinued by Gilead after SIMPLIFY-2, reacquired by Sierra Oncology 2018, Sierra acquired by GSK 2022; Phase 3 MOMENTUM trial designed under Sierra/GSK; NDA 217034 filed March 2023; regular approval September 15 2023; OJJAARA FORMULATION: 100 mg and 150 mg tablets; 200 mg QD (two 100 mg tablets or one 150 mg + one 50 mg) with or without food; PERIPHERAL NEUROPATHY MONITORING: grade 1-2 peripheral neuropathy (numbness, tingling) reported in SIMPLIFY/MOMENTUM; baseline neurological assessment; ACVR1-RELATED ADVERSE EFFECTS: ACVR1 inhibition in bone → reduced BMP signaling → theoretical bone density concern (monitoring); no clinically significant ossification issues at therapeutic doses; EMPLOYEE: 50M GSK Upper Providence PA VP myelofibrosis hematology JAK/ACVR1 inhibitor (ACVR1 mechanism, SMAD1/5/8 hepcidin pathway, MOMENTUM TI 67%, SIMPLIFY-1/SIMPLIFY-2, transfusion independence, anemia of MF); CORITY NULL: CAS 1056634-68-4 → null; NIOSH HD Category 1 absent; first JAK1/JAK2/ACVR1 triple inhibitor absent; ACVR1 hepcidin mechanism absent; ferroportin iron restoration absent; MOMENTUM TI 67% absent).

Surface 2 — Patheon/Thermo Fisher Swindon UK Momelotinib API Manufacturing AI

At Patheon/Thermo Fisher Scientific Swindon UK (Blagrove, Swindon SN5 8RU, United Kingdom; PATHEON SWINDON MOMELOTINIB CONTEXT: Patheon Swindon is a major GSK contract manufacturing site for European-supply small-molecule drug products; momelotinib synthesis: aminopyrimidine scaffold (5-cyano-N-methyl-2-[[3-(4-methylpiperazin-1-yl)-3-oxopropyl]amino]pyrimidine-4-carboxamide type) requiring piperazine ring condensation, cyano group installation, and amide coupling; NIOSH HD CATEGORY 1 AT PATHEON SWINDON: OEB 5 containment (UK COSHH Regulations Schedule 1 classification parallel to US NIOSH HD Cat 1); closed RABS (Restricted Access Barrier Systems); continuous air monitoring; EHS UK regulatory requirement: COSHH assessment for carcinogenic/mutagenic compounds; VELOCITYEHS NULL: CAS 1056634-68-4 → null; NIOSH HD Category 1 absent; JAK1/JAK2/ACVR1 triple absent; ACVR1 hepcidin absent; ferroportin absent; MOMENTUM absent; 45F Patheon Swindon UK API manufacturing scientist momelotinib JAK1/JAK2/ACVR1 14yr).

Surface 3 — UPenn Abramson Cancer Center Philadelphia PA MOMENTUM Trial Site Hematology Oncology Pharmacist AI

At University of Pennsylvania Abramson Cancer Center Philadelphia PA (3400 Civic Center Blvd, Philadelphia PA 19104; UPENN MOMELOTINIB CONTEXT: Abramson Cancer Center was a MOMENTUM (NCT04173494) enrolling site; hematology oncology pharmacy role: verify MF diagnosis with anemia (Hgb <10 g/dL preferred); confirm prior ruxolitinib exposure (MOMENTUM enrolled prior-ruxolitinib patients); review platelet count (momelotinib no platelet restriction unlike pacritinib); OJJAARA PREPARATION AT UPENN: 200 mg QD oral; specialty pharmacy dispensing; TRANSFUSION INDEPENDENCE (TI) ASSESSMENT AT UPENN: TI defined as Hgb ≥8 g/dL AND no RBC transfusion for ≥12 consecutive weeks within 24-week treatment window; baseline transfusion burden assessed (units/12 weeks); hemoglobin monitoring CBC every 2 weeks × 3 months; BMP PATHWAY BIOMARKER MONITORING: serum hepcidin levels (ELISA; Quest Diagnostics or Mayo Clinic laboratory) as exploratory biomarker of ACVR1 engagement; ACVR1 FIBRODYSPLASIA OSSIFICANS CONTEXT AT UPENN: Abramson has a fibrodysplasia ossificans progressiva (FOP) program (ACVR1/ALK2 gain-of-function mutation R206H causes FOP); momelotinib's ACVR1 inhibition studied in collaboration with FOP researchers at Upenn (Dr. Frederick Kaplan lab legacy); SMAD1/5/8 pathway monitoring in MF-anemia bone marrow biopsies as translational research; EHS INSIGHT NULL: CAS 1056634-68-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first JAK1/JAK2/ACVR1 triple absent; ACVR1 BMP SMAD1/5/8 absent; hepcidin suppression absent; ferroportin iron restoration absent; MOMENTUM TI 67% absent; NIOSH HD Cat 1 absent; 39F UPenn Abramson Cancer Center Philadelphia PA hematology oncology pharmacist myelofibrosis 12yr).

Integrating Glyphward into Momelotinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every momelotinib CAS 1056634-68-4 monitoring data ingestion point — before Cority at GSK/Sierra Oncology Upper Providence PA, before VelocityEHS at Patheon/Thermo Fisher Swindon UK, and before EHS Insight at UPenn Abramson Cancer Center Philadelphia PA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-FOURTH MECHANISM CLASS — FIRST JAK1/JAK2/ACVR1 (ALK2) TRIPLE KINASE INHIBITOR EVER FDA APPROVED (NDA 217034 September 15 2023; ACVR1 → SMAD1/5/8 → HAMP hepcidin suppression → ferroportin-1 iron restoration → erythropoiesis; MOMENTUM TI 67% vs 43% danazol; Sierra Oncology/GSK) [5 pts]; GSK Upper Providence PA + Patheon Swindon UK + UPenn Abramson Philadelphia PA [3 pts]; ACVR1 hepcidin mechanism absent; ferroportin iron restoration absent; MOMENTUM absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_momelotinib(cas: str, reading_ugm3: float) -> dict:
    """Scan momelotinib with eighty-fourth-class first-jak1-jak2-acvr1 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_fourth_class_first_jak1_jak2_acvr1_alk2_bmp_type_i_receptor_triple_kinase_inhibitor_ever_smad1_5_8_blocked_hepcidin_hamp_suppressed_ferroportin_sla40a1_iron_restoration_erythropoiesis_momentum_ti_67pct_vs_43pct_danazol_sierra_gsk_nda_217034"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_fourth_class,
    #                    first_jak1_jak2_acvr1_triple, acvr1_hepcidin_mechanism,
    #                    ferroportin_iron_restoration, momentum_ti_67pct

if __name__ == "__main__":
    r = asyncio.run(scan_momelotinib("1056634-68-4", 0.00051))
    print(r)
    # {'hd_category': 1, 'eighty_fourth_class': True,
    #  'first_jak1_jak2_acvr1_triple': True, 'acvr1_hepcidin_mechanism': True,
    #  'ferroportin_iron_restoration': True, 'momentum_ti_67pct': True}